Compare Boston Scientific Corporation (BSX) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Innovative Industrial Properties Inc — how do they compare? Boston Scientific Corporation trades at $43.11 (market cap $66.37B), while Innovative Industrial Properties Inc trades at $63.64 (market cap $1.85B). The key difference: Boston Scientific Corporation is far larger — about 35.9× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 11.93% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | IIPR | |
|---|---|---|
Market Cap | $66.37B | $1.85B |
Sector | Health | Real Estate |
52-Week High | $108.14 | $64.44 |
52-Week Low | $42.63 | $44.58 |
Enterprise Value | $75.94B | $2.23B |
Dividend Yield | — | 11.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
IIPR trades at $63.78, down 1.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 but missing in Q1 2026, with revenue declining to $266M in 2025. Recent news highlights successful debt management, including repaying $282M in senior notes and issuing new debt, while cannabis rescheduling progress offers regulatory tailwinds.
The outlook for IIPR balances a high dividend yield and improved balance sheet against revenue declines and tenant risks. Investment opportunities include potential re-rating from regulatory changes and stable cash flows, but risks involve sector volatility and earnings inconsistency. Analyst sentiment is mixed with a Hold consensus, reflecting cautious optimism amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
